Freshly equipped with two approved meds from Acorda Therapeutics, Frankfurt, Germany’s Merz Therapeutics is kicking its specialty neurology ambitions into high gear.
Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics
XEOMIN® (incobotulinumtoxinA) receives a new therapeutic indication for Switzerland
After years of struggling with hurdles such as generic competition and significantly lower-than-expected sales of its top meds, Acorda Therapeutics is hanging up the gloves with a $185 million deal to sell off its assets and a bankruptcy filing.
XEOMIN® (incobotulinumtoxinA) receives three new therapeutic indications in Australia
Merz Therapeutics Hosts Over 300 International Healthcare Professionals at its First Global “Merz Expert Connect Summit 2023”
Merz's Biologic Xeomin (incobotulinumtoxinA) Receives Approval in the U.S.
Allergan and Merz Pharma yesterday unveiled a $54.4 million settlement with a New York labor union for police officers to dismiss their suit (without any admission of guilt) related to the companies’ clamping down on about a dozen generic competitors for the Alzheimer’s drug Namenda.
FRANKFURT, Germany--(BUSINESS WIRE)--Today, Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, has been granted the use of XEOMIN® for the symptomatic treatment in children and adolescents aged 2 to 17 years and weighing ? 12 kg of chronic sialorrhea due to neurological / neurodevelopmental disorders on EU level.1 The national approvals of the country authorities involved will follow in the next weeks. The U.S. Food and Drug Administration granted approval in December 2020, and the Russian Federal Service for Surveillance in Healthcare in spring 2021.